

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Schwartz )  
Serial No.: 60/191,186 )  
Filed: March 22, 2000 )  
For: NOVEL HYDRAZINE-BASED AND )  
CARBONYL-BASED BIFUNCTIONAL )  
CROSSLINKING REAGENTS )  
Group Art Unit: Unassigned )  
Examiner: Unassigned )

I hereby certify that this paper and the attached  
papers are being deposited with the United States  
Postal Service as first class mail in an envelope  
addressed to:  
Commissioner for Patents  
Washington, D.C. 20231, on this date.

Dale L. Rieger  
Dale L. Rieger

07/06/00  
Date

**PETITION PURSUANT TO 37 C.F.R. §1.48(e), CORRECTION OF INVENTORSHIP  
IN A PATENT APPLICATION, OTHER THAN A REISSUE APPLICATION**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This is a Petition pursuant to 37 C.F.R. §1.48(e), correction of inventorship in a patent application other than a reissue application. This Petition seeks to delete Richard I. Hogrefe as a joint inventor in the above-captioned application. Dr. Hogrefe was inadvertently and without deceptive intent included in the list of joint inventors in the above-captioned application.

Enclosed are the following documents in support of this Petition:

- (a) a statement signed by Dr. Hogrefe indicating that the error in inventorship in the above-referenced application occurred without deceptive intent on his part;
- (b) a check for the fee set forth in 37 C.F.R. §1.17(q) (\$50.00);
- (c) written consent of SOLULINK, INCORPORATED, assignee of the entire title, right and interest in the above-captioned application; and
- (e) a Certificate under 37 C.F.R. §3.73(b) establishing ownership of the instant application by SOLULINK, INCORPORATED.

U.S.S.N. 60/191,186

Schwartz  
PETITION

**Remarks**

Applicant petitions pursuant to 37 C.F.R. §1.48(e) to correct inventorship in the above-captioned application. Any fees, including any submitted herewith if the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this paper or with this application during its entire pendency may be charged to Deposit Account No. 50-1213.

Applicant requests that Richard I. Hogrefe be deleted as a co-inventor in the above-referenced application. Dr. Hogrefe is a not joint inventor of the subject matter of this application, as stated in the attached Statement of Facts. Written consent of the assignee, as required under 37 C.F.R. §1.48(e)(3), is enclosed. Also enclosed is a copy of a Power of Attorney by Assignee appointing the undersigned as attorney for this matter.

\* \* \*

Respectfully submitted,  
HELLER EHRLMAN WHITE & McAULIFFE LLP

By:

  
Stephanie L. Seidman  
Registration No. 33,779

Attorney Docket No. 37154-P753

Address all correspondence to:

Stephanie Seidman, Esq.

HELLER EHRLMAN WHITE & McAULIFFE LLP

4250 Executive Square, 7th Floor

La Jolla, California 92037

Telephone: 858/450-8400

Facsimile: 858/587-5360

EMAIL: sseidman@hewm.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Schwartz  
Serial No.: 60/191,186  
Filing Date: March 22, 2000  
For: NOVEL HYDRAZINE-BASED AND CARBONYL-BASED  
BIFUNCTIONAL CROSSLINKING REAGENTS

**STATEMENT OF FACTS UNDER 37 C.F.R. §1.48(e)**


Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

I, RICHARD I. HOGREFE, hereby declare and state:

- (1) I am not a joint inventor of the claimed subject matter of the above-captioned application.
- (2) Through error, I was joined as an inventor at the time the application was filed.
- (3) Error in inventorship in the above-captioned application occurred without deceptive intention on my part.

Date: 6/26/00

  
RICHARD I. HOGREFE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Schwartz

Serial No.: 60/191,186

Filing Date: March 22, 2000

For: NOVEL HYDRAZINE-BASED AND CARBONYL-BASED BIFUNCTIONAL  
CROSSLINKING REAGENTS

**CONSENT OF ASSIGNEE TO CORRECT INVENTORSHIP UNDER 37 C.F.R. §1.48(e)**

Commissioner for Patents  
Washington, D.C. 20231

Sir:


SOLULINK, INCORPORATED, a corporation organized under the laws of California, with a principle place of business of San Diego, California, U.S.A., is the Assignee of the entire right, title and interest in the above-captioned patent application. A Certificate under 37 C.F.R. §3.73(b) accompanies this Consent.

SOLULINK, INCORPORATED hereby consents to correction of inventorship in the above-captioned application, deleting RICHARD I. HOGREFE as an inventor.

The undersigned (whose title is supplied below) is empowered to act on behalf of the Assignee.

SOLULINK, INCORPORATED

Date: 00.06.2000

  
\_\_\_\_\_  
DAVID A. SCHWARTZ, Ph.D.  
Chief Scientific Officer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Schwartz

Serial No.: 60/191,186

Filing Date: March 22, 2000

For: NOVEL HYDRAZINE-BASED AND CARBONYL-BASED BIFUNCTIONAL  
CROSSLINKING REAGENTS

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

SOLULINK, INCORPORATED, a corporation organized under the laws of California, with a principle place of business of San Diego, California, U.S.A., is the Assignee of the entire right, title and interest in the above-captioned patent application by virtue of an Assignment from the inventor to SOLULINK, INCORPORATED. A copy of the Assignment from the inventor to SOLULINK, INCORPORATED is attached hereto.

The undersigned (whose title is supplied below) is empowered to act on behalf of the Assignee.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SOLULINK, INCORPORATED

Date: 03.26.26

  
\_\_\_\_\_  
David A. Schwartz, Ph.D.  
Chief Scientific Officer